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PD-1 blockade represents a promising treatment in patients with head and neck
squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized
window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether
immunotherapy-mediated treatment effects vary by site of involvement (primary tumor,
lymph nodes) and determine how radiographic tumor shrinkage correlates with pathologic
treatment effect.
Patients and Methods: Forty-four patients enrolled in trial NCT03238365 were treated
with nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil, as
determined by random assignment, followed by surgery on day 31. Radiographic
volumetric response (RVR) was defined as percent change in tumor volume from
pretreatment to posttreatment CT scan. Responders were defined as those with a
10% reduction in the volume of the primary tumor or lymph nodes (LN). Pathologic
treatment effect (PTE) was defined as the area showing fibrosis or lymphohistiocytic
inflammation divided by total tumor area.
Results: Sixteen of 32 patients (50%) with pathologic evidence of LN involvement exhibited
discordant PTE between primary sites and LN. In four patients with widely discordant
adjacent LN, increased PTE was associated with increased infiltration of tumor CD8+ T
cells and CD163+macrophages, whereas stromal regulatory T cells were associated with low
nodal PTE. RVR correlatedwith PTE at both primary tumor (slope = 0.55, p < 0.001) and in LN
(slope = 0.62, p < 0.05). 89% (16/18) of radiographic non-responders with T1–T3 primary
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sites had no (n = 7) or minimal PTE (n = 9), whereas 15/17 (88%) of radiographic responders
had moderate (n = 12) or complete (n = 3) PTE.
Conclusion: Nivolumab often induces discordant treatment effects between primary tumor
sites and metastatic lymph nodes within subjects. This treatment discordance was also
demonstrated in adjacent lymph nodes, which may correlate with local immune cell makeup.
Finally, although thesedataweregeneratedbya relatively small populationsize,ourdatasupport
the use of early radiographic response to assess immunotherapy treatment effect in HNSCC.
Keywords: squamous cell carcinoma of head and neck, nivolumab, immunotherapy, lymph nodes, computed
tomography imaging
INTRODUCTION
Immunotherapy with the use of checkpoint inhibitors targeting
PD-1 has demonstrated survival benefit in the first-line and
second-line treatment of recurrent/metastatic head and neck
squamous cell carcinoma (HNSCC) (1–3). Unfortunately,
however, to date these advances have failed to generate
sustained responses in the majority of patients.
The rapidly-growing interest in PD-1/PD-L1 inhibition for
HNSCC and the use of neoadjuvant therapy underscores the
unmet need for validated methods to accurately assess treatment
response. The gold standard method to evaluate treatment
efficacy remains surgical resection and pathologic examination
of tumor. An ideal surrogate measure would correlate with
pathologic treatment effect, be minimally invasive, permit
rapid and inexpensive tumor evaluation, and be compatible
with longitudinal tracking of tumor response. The Response
Evaluation Criteria in Solid Tumors (RECIST) have been
developed to provide a uniform methodology to assess tumor
response to therapy relying primarily on imaging modalities (4).
For immunotherapeutic agents, including PD-1/PD-L1
inhibitors, a standardized set of consensus guidelines called
“iRECIST” has been specifically designed (5). As the iRECIST
consensus guidelines are not specific to HNSCC, studies relating
radiographic imaging to pathology are needed. Indeed, in 2019
the Society for Immunotherapy of Cancer failed to reach
consensus on the most appropriate radiographic method for
quantifying HNSCC treatment response (6). Moreover, the 2019
iRECIST guidelines recommend “response assessment every 6–
12 weeks”, which falls outside the timeframe of many window-
of-opportunity trials (WOT), including the one investigated here
(5). In this study, we follow individual lesions over a short course
of immunotherapy by CT, and then compare CT results to the
treatment effect demonstrated by pathological examination of
resected tumor tissues. By comparing treatment effects within a
patient, this format attempts to limit the challenges to treatment
response assessment created by tumor heterogeneity and patient
variability. Indeed, this approach has been validated for HPV+
HNSCC treated with traditional platinum-based chemotherapies
prior to definitive resection (7).
We conducted an analysis of our results from a prospective
preoperative window-of-opportunity trial (WOT) of nivolumab
with or without tadalafil to examine whether response differs
between different tumor sites and whether radiographic response
correlates with pathology findings. The primary endpoint and
main results of the clinical study, including biomarker analysis,
will be reported separately.
METHODS
Patients
Following approval by the Institutional Review Boards of
participating institutions, 44 patients with newly diagnosed,
resectable HNSCC were enrolled in a WOT (NCT03238365) and
had evaluable imaging and pathology for analysis. Within 28 days of
enrollment patients had undergone baseline pretreatment and CT
scan, as well as a biopsy of their primary tumor. Following 4 weeks
of treatment, patients underwent a second CT, followed by same-
day surgical resection of the primary tumor and lymph node
dissection. Patient demographics and tumor details are listed in
Supplementary Table 1 (S1). All patient data were pooled,
regardless of treatment status with tadalafil.
Treatment
All patients enrolled in the study received nivolumab 240 mg
intravenously every 2 weeks for 2 doses (Opdivo, Bristol-Myers
Squibb, NY, USA). To assess the effects of PDE5 inhibition on
nivolomab efficacy, on day 0 patients were randomly assigned 1:1
to receive either nivolumab alone or nivolumab plus the PDE5
inhibitor tadalafil (Cialis, Eli Lilly, IN, USA), 10 mg orally once
per day.
Pathologic Evaluation
Following surgical resection of primary site and lymph nodes on
day 31, specimens were processed and analyzed by two head and
neck pathologists. The primary specimen and all abnormal
lymph nodes were sectioned in their entirety, and all slides
containing tumor were included in the analysis. Pathologic
treatment effect (PTE) was defined as the area of tissue
exhibiting predefined histologic criteria of tumor response as a
percentage of total tumor area (S2) (8). Tumors with PTE of
≥20% were defined as “moderate” responders, while those with
PTE <20% were defined as “minimal” responders. LN with 0 or
100% PTE were defined as pathologic “non-responders” or
“complete responders”, respectively. Histologic analysis of
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primary tumor (Figures 1A, B) and lymph nodes (Figures 1B, C)
reveal the criteria used to define the pathologic treatment effect. For
example, Figure 1C demonstrates a LN with a 100% PTE, with no
evidence of tumor and robust markers of inflammation,
macrophage reaction, multinucleated giant cells, and granulomas.
In contrast, Figure 1D shows an adjacent LN from the same patient
with 0% PTE, with visible nests of tumor still present and no
evidence of fibrosis or chronic inflammation.
Immunohistochemistry
To investigate potential differences in the tumor microenvironment
(TME) between adjacent lymph nodes with disparate treatment
effects, surgical specimens were stained using antibodies to PD-L1
(clone E1L3N 1:50, Cell Signaling, MA, USA), CD8 (clone SP57
prediluted, Roche, Switzerland) CD163 (clone MRQ-26 prediluted,
Roche) or FoxP3 (clone SP97 1:100, Spring Bioscience, CA, USA) to
determine the number of positive cells per high-powered field. For
each tumor assessed, image analysis was performed at three different
regions of interest (ROI) (tumor-stromal interface, tumor, and
stroma). For each ROI, three separate areas representing the
highest concentrations of target cell population were analyzed per
slide. Quantitative analysis of CD8, CD163, and FoxP3 was
performed using Visiopharm (Visiopharm, Denmark), utilizing a
linear type Bayesian classification to determine cell positivity. PD-L1
expression was performed semi-quantitatively, with cell counts
determined by pathologist interpretation (<1, 1–20, and >20%
TPS score). Importantly, patients receiving tadalafil were excluded
from all TME analysis, in order to avoid potential confounding
effects of tadalafil on TME.
Radiographic Evaluation
Pretreatment CT scans (CTi) and posttreatment CT scans (day of
surgery) (CTf) were compared to determine radiographic
volumetric response (RVR). Both the primary tumor site as well
as any lymph nodes identified as abnormal on the pretreatment
scan were categorized as tumors and were measured using a
modified radiographic evaluation to account for the short course
of the neoadjuvant treatment. For each tumor, diameter was
measured in three dimensions to calculate tumor volume (V),
using the equation V = 43 p(x axis * y axis * z axis) : RVR of both
primary site (RVRPS) and lymph node(s) (RVRLN) was calculated
as the percent change between pretreatment volume (Vi) and




Patients with n abnormal lymph nodes received an aggregate
lymph node RVR (RVRLN ) calculated as a weighted average
according to the equation:
RVRLN =
(RVR1*Vi1) + (RVR2*Vi2) +⋯ (RVRn*Vin)
Vi1 + Vi2 +⋯Vin *
100%
Primary site tumors that decreased in volume by at least 10%
(RVRPS ≥ 10%) were categorized as “Decreased”, while primary
site tumors that increased in size by at least 10% (RVRPS ≤ -10%)
were categorized as “Increased”; all other primary site tumors
were categorized as “Stable”. These same cutoffs were also used to
categorize each patient’s nodal response as “Decreased”, “Stable”,
or “Increased”. These measures were combined to describe
overall volumetric response (Figures 4A, B). Additionally,
treatment response of individual primary tumors and lymph
nodes were quantified and correlated to their pathologic findings
(Figures 4C, D).
Statistical Analysis
The association of RVR and pathologic TE correlation was
evaluated using linear regression analysis for primary tumor
data and using mixed effects linear regression for LN data to
account for correlation among multiple observations from some
subjects. RVR and PTE were transformed using logit
transformation prior to analysis. Values of 100% were set to
99.9% and values of 0% were set to 0.1% prior to applying the
logit transformation. All RVR demonstrating tumor growth were
coded as RVR = 0%. The slope of the linear regression line on the
logit-transformed data was the estimate of association. For
plotting, the estimated curve was back-transformed to the
percentage scale. Average PTE between primary site and
lymph nodes were compared by unpaired, two-tailed t-test.
Regression analysis was performed using SAS 9.4 and SAS/
STAT 15.2 (SAS Institute, Cary, NC, USA). Graphs were
designed using Graphpad Prism 7 software (GraphPad
Software, CA, USA).
RESULTS
Discordant TE Between Primary Site
and Lymph Nodes Suggests Increased
Therapeutic Response at Lymph Nodes
Compared to Primary Tumor
Of the 44 patients evaluated in this study, 32 presented with
disease in the lymph nodes in addition to the primary site. To
determine whether nivolumab differentially affects tumor
regression at the primary tumor site compared to lymph
nodes, we compared matched pathologic TE by site within
patients. Interestingly, half (16/32, 50%) of patients with
regional disease exhibited discordant TE, defined by a
difference in PTE of at least 20% (Figure 2A). Moreover, this
discordance was driven by an increased TE in LN (average TE
+/- SEM: 42.2 +/-6.8 %) compared to primary site (average TE
+/- SEM: 26.3 +/- 5.1%) (p = 0.05). In support of this, 14 of the 40
lymph nodes analyzed (35%) had a higher TE than their matched
primary site, while only 5 of 40 (12.5%) nodes had lower TE than
their matched primary site (Figure 2B). Chi square analysis
demonstrated that tadalafil did not significantly alter the rate of
discordant TE compared to patients receiving placebo (44%
discordance in tadalafil-treated group versus 60% discordance
in placebo group, p = 0.373).
Comparison of Tumor Microenvironment
Between Matched Lymph Nodes With
Widely Discordant Pathologic TE
Interestingly, analysis of patients not receiving tadalafil revealed
a small cohort of four patients exhibiting widely disparate PTE
between adjacent lymph nodes, including one patient with
Merlino et al. HNSCC Nivolumab: CT vs Pathology





FIGURE 1 | 57 y/o M with P16+, cT2N2 oropharyngeal SCC. (A) CT imaging was performed on day 0 (pretreatment) and day 31 (posttreatment) to determine
radiographic treatment effect; representative coronal imaging demonstrates the primary tumor (box), lymph node A (short arrow), and lymph node B (long arrow).
(B) Low magnification (left) and high magnification (right) imaging demonstrates a tumor with partial (52%) pathologic treatment effect. In the high magnification
image, a nest of viable tumor cells (dashed line) is bordered by lymphocytic infiltration (short arrow), macrophages (long arrow), and fibrosis (arrowhead). (C) Lymph
node A demonstrated 100% pathologic TE, with no tumor cells evident in the node. High-powered magnification (right) reveals a poorly-formed granuloma (arrow)
and extensive fibrosis (arrowhead), leading to distortion of the normal LN architecture. A residual germinal center is also present (dashed lines). (D) Lymph node B
exhibited 0% pathologic TE, as seen in the high-magnification image (right). The normal lymph node architecture is preserved (long arrow), and a nest of malignant
cells confirms tumor invasion (short arrow).
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complete resolution of tumor in one node and absence of any TE
in an adjacent node (Figure 3A). To determine whether this was
due to differences in the immune microenvironment, CD8+
cytotoxic T cells, FoxP3+ Treg cells, and CD163+ macrophages
were quantified in the tumor and surrounding stroma of the LNs
of interest (Figures 3B–H). Although this cohort is too small to
draw conclusions, comparison of immune infiltrates in these
matched nodes revealed a trend toward increased CD8+ T cells
(Figure 3C) and CD163+ macrophages (Figure 3D) in tumors of
nodes with increased TE, while increased stromal Tregs (FoxP3+)
were associated with nodes demonstrating reduced TE (Figure
3H). Interestingly, there did not appear to be any relationship
between PD-L1 staining intensity and TE (Figure 3B).
Radiographic Volumetric Response
Correlates With Pathologic TE
We next sought to determine whether changes in tumor size
quantified by CT accurately reflected true treatment efficacy in
eliminating tumor cells. To do this, we first categorized each
patient as a radiographic responder or non-responder based on
the change in size of both the primary tumor as well as any
abnormal lymph nodes (Figure 4A). We then compared these
results to the patient’s PTE, the gold standard of treatment effect
determination. Interestingly, all eight patients with T4 primary
tumors were categorized as radiographic non-responders, despite
the fact that 38% (3/8) of T4 tumors demonstrated moderate
PTE. Conversely, only 11% (2/18) of “radiographic non-responder”
patients with T1-T3 primary tumors exhibited moderate pathologic
treatment effect. Among T1-T3 “radiographic responder”
patients, 88% (15/17) exhibited moderate (> 20% PTE) or
complete PTE. This suggests that radiographic quantification of
treatment response may not be effective in patients with T4
primary tumors.
Quantitative analysis of individual tumor sites demonstrated
a significant correlation between RVR and pathologic treatment
effect. This correlation between RVR and PTE was significant
A
B
FIGURE 2 | Analysis of individual patients reveals frequent discordance between pathologic TE and primary site and lymph nodes. (A) Of the 44 patients analyzed,
32 had lymph nodes positive in addition to primary site; 16 of the 32 (50%) patients exhibited discordant PTE. (B) Discordant TE is driven primarily by an increased
PTE at LN relative to primary site. Of the 40 nodes analyzed, only 5 (12.5%) (red lines) had higher PTE than their primary site; conversely, 14 (35%) (green lines)
nodes had higher PTE than their matched primary site. Nodes with concordant PTE at primary site are depicted in black.
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both at the primary tumor site (Figure 4C) (slope = 0.55; 95% CI
0.25, 0.85; p < 0.001) as well as at metastatic lymph nodes (Figure
4D) (slope = 0.65; 95% CI 0.22, 1.09; p < 0.05).
One patient had newly enlarged lymph nodes without
necrosis or abnormal shape on the posttreatment CT and the
final pathology revealed these lymph nodes to be benign.
DISCUSSION
Our study investigated HNSCC patients treated with a brief
course of neoadjuvant nivolumab prior to surgical resection and
evaluated treatment effect by CT imaging as well as by pathology.
Because most patients included in this study had multiple sites of
malignancy [primary and lymph node(s)], we had the
opportunity to compare treatment effect of nivolumab within
individual patients. This analysis revealed that patients with
multiple sites of disease frequently exhibit discordant
responses, demonstrating that even within a patient the tissue
subtype and tumor microenvironment (TME) plays a substantial
role in nivolumab efficacy. Moreover, our finding that pathologic
lymph nodes frequently displayed more favorable treatment
effect than the primary site suggests that immune cell
concentration and/or cytokine makeup could influence the
efficacy of nivolumab; future studies are needed to determine
whether this is the case. Indeed, a 2017 study of the TME by
Jimenez-Sanchez et al. revealed that the TME may influence
tumor progression between metastases within a patient (9). This
is hinted by the comparison of nodes with discordant treatment
effects, which demonstrated an increased number of tumor-
infiltrating CD8 T cells and CD163+ macrophages and
decreased stromal FoxP3+ Tregs in nodes with 100% TE. This
hypothesis-generating study suggests that further interrogation
and comparison of the TME between responding and
nonresponding tumor sites within a patient may provide
valuable insight into the mechanisms of tumor resistance to
checkpoint inhibition. Further investigation of the TME is
necessary to understand the mechanism underlying these
findings and determine whether they play a role in resistance
to immunotherapies such as nivolumab.
We also demonstrate that in 4 weeks of treatment, RVR for
individual tumors correlates with pathologic TE, both at primary
sites (slope = 0.55) as well as at metastatic lymph nodes (slope =
0.65). Moreover, we describe a radiographic algorithm that
detected minimal or no pathologic response to nivolumab





FIGURE 3 | Comparison of the tumor microenvironment in matched lymph nodes of four patients with highly discordant PTE. (A) List of matched lymph node PTE.
(B) PD-L1 expression did not appear to influence PTE between discordant LNs. (C) Histologic analysis of tumor-infiltrating immune cells demonstrated a trend
toward increased CD8 T cells and (D) increased CD163+ macrophages in LN with maximal PTE; (E) no detectable trend was detected in tumor-infiltrating FoxP3+
Tregs. (F) No detectable relationship was found between stromal CD8 T cells and PTE, but (G) stromal CD163+ macrophages were increased in LN with maximal
TE. (H) 75% of the max TE LN contained no stromal FoxP3+ Tregs, in sharp contrast to their matched min TE LN.
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value (NPV) of 81% (21/26); excluding patients with T4 primary
tumors increased this NPV to 89% (16/18). Conversely, the
algorithm detected moderate or complete pathologic treatment
response (pathologic TE ≥20%) with a positive predictive value
75% (15/20) or 88% (15/17) if T4 tumors are excluded. One
possible explanation for these findings is that the burden of
disease in T4 tumors may slow immune cell infiltration and
macrophage debris clearance, delaying radiographic evidence of
tumor involution to beyond the window of time investigated.
Additionally, pretreatment CT scans were performed up to 28
days prior to first nivolumab dose. While this has could result in
underreporting of RVR across all tumors, additional tumor
growth during this time may have been more prominent in
larger, more aggressive T4 tumors. While this algorithm was
generated retrospectively and therefore requires validation with
additional patient populations to confirm its utility, it provides a
valuable starting point by which future HNSCC tumors can be
monitored over brief window trials.
By demonstrating the discordant treatment effects between
primary sites and adjacent nodes, this study achieves several
ends. First, it supports the findings of other studies
demonstrating similar discordance in other solid malignancies,
such as lung cancer (10, 11). Importantly, however, unlike the
aforementioned studies, this research utilizes the gold standard
of tumor progression, histopathology, to compare true treatment
effect to that which is demonstrated by CT imaging. This has
several important consequences. First, it highlights the potential
confounder of pseudoprogression, by confirming that tumor
growth on CT does not necessarily equate to expansion of
malignant cells. Second, this study demonstrates that this
pseudoprogression may be particularly prominent in large,
bulky disease with T4 primary lesions. This is of particular
importance in head and neck cancer window trials, since many
window trials do provide a long enough window of time to follow
tumors until pseudoprogression can be confirmed by CT
imaging. Finally, it confirms discordance at adjacent sites by
histopathology shortly after administration of checkpoint
inhibition, which is not possible by CT imaging alone, due to
the need for repeat imaging to rule out pseudoprogression.
Landmark studies by Ferris et al. in 2016 (3) and Cohen et al. in
2019 (2) showed that treatment with PD-1 inhibitors (nivolumab or
pembrolizumab) increased overall survival in patients with platinum-
refractory recurrent or metastatic HNSCC. More recently, the results
of KEYONOTE-048 established pembrolizumab +/- chemotherapy
as the standard of care in the first-line treatment of recurrent or
metastatic HNSCC. However, only a small fraction of patients with
HNSCC derives benefit from immunotherapy. (2) With a multitude
of new studies expected in the near future, this work underscores the
importance of understanding response patterns in HNSCC and that





FIGURE 4 | Correlation of radiographic volumetric response and pathologic treatment effect. (A) Assignment of patients to radiographic volumetric response groups,
based on the percent change in volume of both the primary tumor and the combined volume of all abnormal lymph nodes. (B) All 8 patients with T4 primary tumors
(red outlines) were characterized as radiographic non-responders. 18 patients with T1–T3 primary sites were designated radiographic non-responders (solid red);
89% (16/18) exhibited no pathologic treatment effect (n = 7) or minimal PTE (n = 9). Of the 17 patients designated radiographic responders (blue), 15 (88%)
demonstrated moderate (n = 12) or complete (n = 3) treatment effect. (C) Quantitative analysis of primary sites demonstrates a strong positive correlation between
RVR and pathologic TE (slope = 0.55, p < 0.001) of individual tumors, despite the failure of T4 primary tumors (red outlined circles) to demonstrate any RVR.
(D) Analysis of abnormal nodes demonstrates a significant correlation (slope = 0.65, p < 0.05). For (D), each data point represents a single node.
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may inform treatment decision-making as well as assist in the
evaluation of immunotherapy efficacy.
There are several limitations to this study. First, the algorithm
utilized to categorize patients as radiographic responders/non-
responders was generated after patient data were collected. The
efficacy of this algorithm to detect patients with treatment failure
will need to be validated by applying the algorithm in a
prospective trial. Second, the sample size of 44 individuals
analyzed is relatively low, limiting the ability to extrapolate
these findings across patient populations. The small cohort of
four patients with discordant LN TE prevents quantitative
assessment of the data generated, limiting the findings to
qualitative trends. Finally, although tadalafil was not found to
significantly alter the rate of discordant TE at different tumor
sites, this does not definitively eliminate the possibility of
treatment-mediated confounding effects. Despite these
limitations, our observations add important context to the
growing body of literature describing HNSCC treated with
immunotherapy, and lays the foundation for future studies
that can build off of these findings. We plan to further
correlate both CT as well pathologic TE findings with immune
biomarkers from blood and tissue.
Because of its design as a window-of-opportunity trial, the
duration of pharmacologic treatment (4 weeks) is significantly less
than the treatment settings in which RECIST are commonly
applied. (5) However, window trials represent an important tool
in evaluating the efficacy of novel HNSCC treatment regimens,
allowing patients access to novel therapies without delaying
definitive surgical therapy. Indeed, numerous window trials for
HNSCC exist in the literature, including neoadjuvant treatment
with EGFR inhibition (12–15) and/or immunotherapy (16, 17). A
recent study by Sadeghi et al. (7) demonstrated a correlation
between pathologic and radiographic responses in HPV+
oropharyngeal cancers in the context of a window-of-opportunity
trial with neoadjuvant cisplatin/docetaxel. Our study advances this
work by providing additional data on a broader range of HNSCC
subtypes, and to our knowledge is the first such analysis of patients
treated with an immune checkpoint inhibitor.
In conclusion, we demonstrated discordant responses between
primary tumor and regional metastatic lymph nodes after brief
neoadjuvant preoperative nivolumab therapy in HNSCC. We
suggest that this may correlate with variations in local immune
response. Moreover, our study demonstrated that neoadjuvant
immunotherapy can induce rapid, quantifiable changes in tumor
volumes assessed by CT scan. We applied novel radiographic
volumetric response criteria and showed that radiographic
response correlates with pathologic treatment effect. We propose
that future neoadjuvant window of opportunity trials with
immune checkpoint inhibitors incorporate and further validate
these radiographic response criteria.
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